Alpha-synuclein stepwise aggregation reveals features of an early onset mutation in Parkinson’s disease

被引:0
|
作者
Guilherme A. P. de Oliveira
Jerson L. Silva
机构
[1] Federal University of Rio de Janeiro,Institute of Medical Biochemistry Leopoldo de Meis, National Institute of Science and Technology for Structural Biology and Bioimaging, National Center of Nuclear Magnetic Resonance Jiri Jonas
[2] University of Virginia,Department of Biochemistry and Molecular Genetics
来源
关键词
D O I
暂无
中图分类号
学科分类号
摘要
Amyloid formation is a process involving interconverting protein species and results in toxic oligomers and fibrils. Aggregated alpha-synuclein (αS) participates in neurodegenerative maladies, but a closer understanding of the early αS polymerization stages and polymorphism of heritable αS variants is sparse still. Here, we distinguished αS oligomer and protofibril interconversions in Thioflavin T polymerization reactions. The results support a hypothesis reconciling the nucleation-polymerization and nucleation-conversion-polymerization models to explain the dissimilar behaviors of wild-type and the A53T mutant. Cryo-electron microscopy with a direct detector shows the polymorphic nature of αS fibrils formed by heritable A30P, E46K, and A53T point mutations. By showing that A53T rapidly nucleates competent species, continuously elongates fibrils in the presence of increasing amounts of seeds, and overcomes wild-type surface requirements for growth, our findings place A53T with features that may explain the early onset of familial Parkinson’s disease cases bearing this mutation.
引用
收藏
相关论文
共 50 条
  • [41] Familial Parkinson's disease - The awakening of alpha-synuclein
    Goedert, M
    NATURE, 1997, 388 (6639) : 232 - 233
  • [42] Sumoylation of alpha-synuclein in the pathogenesis of parkinson's disease
    Engelender, S.
    JOURNAL OF NEUROCHEMISTRY, 2019, 150 : 48 - 48
  • [43] Autoantibodies to alpha-synuclein in inherited Parkinson's disease
    Papachroni, Katerina K.
    Ninkina, Natalia
    Papapanagiotou, Angeliki
    Hadjigeorgiou, Georgios M.
    Xiromerisiou, Georgia
    Papadimitriou, Alexandros
    Kalofoutis, Anastasios
    Buchman, Vladimir L.
    JOURNAL OF NEUROCHEMISTRY, 2007, 101 (03) : 749 - 756
  • [44] A Characterization of Misfolded Alpha-Synuclein in Parkinson's Disease
    Shannon, Daniel
    Bugada, John-Paul
    Collins, Ethan
    Fischer, Ellie
    Hellard, Delaney
    Hoffman, Trevor
    Kellogg, Nick
    Peters, Kyle
    Poetker, Garret
    Young, Logan
    Diao, JiaJie
    FASEB JOURNAL, 2020, 34
  • [45] Alpha-Synuclein and Mitochondrial Dysfunction in Parkinson’s Disease
    Dolgacheva L.P.
    Fedotova E.I.
    Abramov A.Y.
    Berezhnov A.V.
    Biochemistry (Moscow), Supplement Series A: Membrane and Cell Biology, 2018, 12 (1) : 10 - 19
  • [46] Alpha-synuclein and presynaptic functionImplications for Parkinson’s disease
    Simon Lykkebo
    Poul Henning Jensen
    NeuroMolecular Medicine, 2002, 2 : 115 - 129
  • [47] Role of alpha-synuclein and tau in Parkinson's disease
    Trojanowski, JQ
    MOVEMENT DISORDERS, 2004, 19 : S2 - S2
  • [48] Targeting Alpha-Synuclein for the Treatment of Parkinson's Disease
    Rohn, Troy T.
    CNS & NEUROLOGICAL DISORDERS-DRUG TARGETS, 2012, 11 (02) : 174 - 179
  • [49] The central role of alpha-synuclein in Parkinson's disease
    Halliday, G.
    JOURNAL OF NEUROCHEMISTRY, 2015, 134 : 54 - 54
  • [50] Alpha-synuclein and the Parkinson's disease drug pipeline
    Espay, Alberto J.
    McFarthing, Kevin
    PARKINSONISM & RELATED DISORDERS, 2023, 111